WebPhase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma : Japan clinical oncology group study JCOG0211. / Yamaguchi, Motoko; Tobinai, Kensei; Oguchi, Masahiko et al. In: Journal of Clinical Oncology, Vol. 27, No. 33, 20.11.2009, p. 5594-5600. Research output: Contribution to journal › Article ... Web23 ott 2012 · 山口氏らはJCOG0211-DI試験において、未治療限局期鼻NKTCLでAnn Arbor病期分類IE期または頸部リンパ節浸潤のIIE期の患者を対象に、RT-DeVIC療法を …
Stage II Contiguous Adult Diffuse Mixed Cell Lymphoma
Web1 ott 2009 · phoma: Results of a phase I portion of JCOG0211-DI. Blood 106:754A, 2005 (abstr 2685) 34. A predictive model for aggressive non-Hodgkin’s. lymphoma: The … Web– JCOG0211 (PI/II) – Concurrent chemoradiotherapy (RT-2/3DeVIC) • Newly-diagnosed stage IV, relapsed/refractory NKTCL – NKTSG (Multinational trials in East Asia) – SMILE … medication for prinzmetal angina
Phase I/II Study of Concurrent Chemoradiotherapy for Localized …
Web5 ott 2009 · Purpose To explore a more effective treatment for localized nasal natural killer (NK)/T-cell lymphoma, we conducted a phase I/II study of concurrent … Web28 feb 2024 · In addition, in a retrospective study of 150 ENKL patients who underwent RT-DeVIC in clinical practice at 31 institutions in Japan, only 2 patients with CR to primary treatment underwent HDC/AHSCT, and 1 of those patients developed a second cancer in the radiation volume [3]. 5-year OS rates were good in both the JCOG0211 trial and the … WebAfter JCOG0211 study, 49% of RT was designed according to JCOG0211 RT protocol, while 80% or more were not compliant RT protocol before/during JCOG0211. The local control was 74% for all population, 88% of local control rate was observed in patients treated with RT compliant with JCOG0211 RT protocol (extended RT), while 70% in patients nabco seattle wa